KRAS Mutation Colorectal Cancer: 15 Real Stories

15 stories match colorectal cancer and KRAS mutation. 14 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Stage IV MSI-H KRAS-mutant colorectal adenocarcinoma: severe pembrolizumab-associated hypercalcemia resolved with steroids and zoledronic acid

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: KRAS G12xa mutation; MSI-H; BRAF wild type; NRAS wild type; PTH low-normal

Metastatic Site: liver

After the second pembrolizumab dose, severe hypercalcemia and electrolyte abnormalities resolved with high-dose glucocorticoids, zoledronic acid, and supportive care; cancer response was not yet described.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Stage IV KRAS-mutant colorectal cancer with bilobar liver metastases: multimodality treatment and no evidence of disease

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: KRAS-mutated; BRAF wild-type; mismatch repair proficient

Metastatic Site: liver

After second liver resection, follow-up MRI at 8 weeks showed continued response at the SABR site and no recurrent disease; she was receiving adjuvant capecitabine and remained well.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Metastatic rectal cancer responding well after intensive treatment despite severe chemotherapy complications

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: KRAS exon 4 mutation, BRAF wild-type, PD-L1 CPS 2

Metastatic Site: liver, lung

After more than 14 months of treatment, the primary rectal tumor and most lung metastases had been resected, liver lesions had largely regressed, and he was described as near NED while continuing maintenance capecitabine plus bevacizumab.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage III Colorectal AdenocarcinomaColorectal Cancer

Stage III colon cancer followed by a second gastro-oesophageal adenocarcinoma

Patient Info: Anonymized, Female | Stage III

Biomarkers: KRAS-mutated, NRAS-negative, BRAF-negative

After surgery and 4 cycles of CAPEOX, imaging initially showed no metastases. Later imaging showed new bilobar liver lesions, and a separate primary gastro-oesophageal adenocarcinoma was diagnosed about 1 year after the colon cancer.

PubMed Central
OutcomeNot reported
Bill, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV KRAS Colorectal Cancer: Bill's Patient Story

Patient Info: Bill, Male, 40s | Stage IV

Biomarkers: KRAS mutation

Metastatic Site: liver; lung; brain

Bill has Stage IV KRAS G12A-mutated colon cancer with liver, lung, and brain metastases. After multiple surgeries, ablation, Gamma Knife, and repeated chemotherapy, tumors shrank and he moved to lifelong maintenance chemotherapy every 2 weeks as of March 2025.

The Patient Story
OutcomeLiving With Cancer
Lauren, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV KRAS Colorectal Cancer: Lauren's Patient Story

Patient Info: Lauren Bimage, Female, Under 40 | Stage IV

Biomarkers: Patient-reported KRAS-mutated colon cancer

Metastatic Site: chest; abdominal/peritoneal lining; spine/back

As of September 2024, Lauren was living with both Stage IV breast cancer and Stage IV colon cancer. Colon cancer markers were described as low/normal, while biopsy showed the persistent back/spine disease was breast cancer.

The Patient Story
OutcomeLiving With Cancer
Kris, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV KRAS Colorectal Cancer: Kris's Patient Story

Patient Info: Kris Sokolowski, Male, 40s | Stage IV

Biomarkers: KRAS mutation

Metastatic Site: Liver; sternum; spine; lymph nodes; omentum/abdominal…

As of May 2022, Kris was living with Stage IV KRAS G13D-mutant colorectal cancer. Most tumors had been stable or shrinking, but abdominal/omental disease continued to grow despite additional full-strength chemotherapy, so clinical-trial and immunotherapy options were being explored.

MD Anderson
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Severe immune thrombocytopenia during treatment for metastatic colon cancer

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: KRAS-mutated; microsatellite stable; BRAF-wild type.

Metastatic Site: bilateral ovaries; pelvis; peritoneum; mesenteric…

After multiple metastatic recurrences and treatment changes, she died from progressive colon cancer; oxaliplatin had been permanently stopped after antibody-confirmed immune thrombocytopenia.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Metastatic Right-Sided Colon Cancer With an NRG1 Fusion

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: KRAS mutation; POMK-NRG1 fusion

Metastatic Site: liver|lungs

He had persistent metastatic disease after 16 months of afatinib and entered a phase I trial in January 2020.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Treatment-Related Inflammation Mimicked Metastatic Colon Cancer Recurrence

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: KRAS mutation

Metastatic Site: liver|peritoneum

Biopsy showed that new lymph-node, liver, and spleen findings were a treatment-related sarcoid-like reaction rather than recurrence, and 18 months of surveillance found no evidence of cancer.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Colorectal AdenocarcinomaColorectal Cancer

Colon Cancer Metastasis Found Inside a Thyroid Nodule

Patient Info: Anonymized, Male, 50s | Stage Metastatic/Advanced

Biomarkers: KRAS mutated; thyroid metastasis CDX2 positive and CK20 positive; PAX8/TG/TTF-1 negative

Metastatic Site: lungs|thyroid

Follow-up was planned after thyroid surgery, with no adjuvant treatment for the coexisting low-risk thyroid lesion.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Metastatic Colon Cancer With KRAS, NRAS, and BRAF Mutations

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: KRAS exon 3 ; NRAS exon 2 ; BRAF exon 10 ; PIK3CA exon 2 .

Metastatic Site: liver

The liver metastases progressed despite FOLFOX and bevacizumab, and he died within one year of the initial diagnosis.

PubMed Central
OutcomeIn Memory